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Abstract. STEMCHEM is a COST action aiming to
target causes of drug resistance in cancer stem cells.
Cancer stem cells are cells which are believed to be re-
sponsible for the larger part of the regenerative capacity
of cancers. They are also thought to be similar to adult
stem cells in that they do not proliferate most of the time
and are thus resistant to many kinds of chemotherapy.
The action brings together labs around Europe in both
biological and chemical fields to work together in this
regard. Biologists targeting individual stem-cell related
molecules as well as stem cell phenotypes (like the un-
differentiated state), test chemicals from numerous labs
for activity in high throughput screens, with the aim of
identifying new drug targets. This COST action, like
most others, offers opportunities for Malta, both in a
general way and also particularly for a small country
with small labs.
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COST (European Cooperation in Science and Tech-
nology) is one of the longest running European Scientific
programmes, which allows for better coordination of na-
tionally funded research at a European level.
Unlike the FP7/Horizon 2020 instruments which work
in a top-down manner with calls being issued by the
Commission as to what areas of research it is interested
to fund, COST works in a bottom up or grass-roots ap-
proach. Any group of labs or interest groups from a few
different countries can get together, start up a COST
action, after it is vetted by the COST central adminis-
tration in Brussels and then open it up to other part-
ners to join in. This information is usually passed on
the national contact point organisation (in Malta the
MALTA COUNCIL FOR SCIENCE AND TECHNO-
LOGY), who informs interested potential participants
on a regular basis of the newest set of COST actions to
be set up.
For a small country like Malta, with small labs and
minimal funding, where entry into the big consortia
characteristic of the FP programmes has always been
difficult (and I speak from experience here), COST al-
lows the development of important scientific contacts,
which may later lead to participation in such collabor-
ations. It also allows increased scientific exposure of
research done in our laboratories.
The University of Malta’s Anatomy Department
through a number of graduate students under Pierre
Schembri-Wismayer’s supervision has been working for
some time on inducing differentiation of leukaemia
cell lines using a variety of natural extracts, some of
which have been published (Agius Anastasi, Cassar &
Schembri-Wismayer, 2012) and others of which not yet
due to the possibility of developing intellectual property
for the University. The research uses the HL60 leuk-
aemia cell line as an initial screen since it allows dif-
ferentiation into both monocytic and granulocytic cell
types.
When reviewing newer COST actions, Prof. Janet
Mifsud, COST coordinator in Malta brought to our
attention an action entitled “Chemical Approaches to
Targeting Drug Resistance in Cancer Stem Cells” in
December 2011. This seemed interesting so I, (Pierre
Schembri-Wismayer) approached Prof. Mifsud about
joining and was elected a member on the managerial
board of the Action, representing Malta. I attended the
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kick-off meeting in Brussels, with the rest of the man-
agement committee since we got involved early on. The
meetings of the management committee (which tend to
be combined with workshops in this Action in order to
allow more to get done at once) allow the regulation of
the budget and of how the action is set to work.
Cancer stem cells (CSC) are a subpopulation of cells
within tumours that exhibit enhanced tumor-initiating
attributes and are a major contributing factor to cur-
rent cancer therapy failure. The CSC phenotypic state
comprises distinct molecular and functional differences
that underpin resistance to current treatments and the
unique ability spread and to seed new tumors through-
out the body. This insight of this particular sub-
population of cells and its capability of repopulating
tumours where most cells have been killed by conven-
tional therapy, necessitates an entirely new approach to
cancer drug development. This action aims to unite ex-
pertise in rational drug design and medicinal chemistry
with biomedical investigators dedicated to understand-
ing the mechanisms governing drug resistance in cancer
stem cells. Thus it aims to develop effective methods for
identifying novel compounds and drug candidates that
target these drug-resistant cancer cells. One such way in
fact would be to cause these cancer stem cells to differ-
entiate into less stem-like cancer cells so that they can
then be killed by more standard chemotherapy. The
rationale and basis behind the action are reviewed in
more detail in a recent publication from the consortium
(Sotiropoulou, Christodoulou, Silvani, Herold-Mende &
Passarella, 2014).
During the first meeting in Brussels we also chose a
number of important positions such as the Chair (Prof.
Daniele Passarella, a chemist from University of Milan,
Italy who had initiated the action) and Vice Chair (Prof.
Marija Balic, a medical doctor and biologist from Aus-
tria) as well as a number of important positions relating
to specific instruments of the actions, (such as Dr Gabri-
ela Almeida from Portugal who is in charge of short term
scientific missions - STSMs - more about these later).
It was decided for example that members were divided
into three working groups, one of chemists, one of bio-
logists and one of pharmaceutical and medicinal chem-
ists, including specialists in computational prediction of
drug-target interactions. Our lab joined working group
one, primarily for biologists. However, even within this
group, there were numerous variations, which enriched
the meetings since attending the various workshops not
only allowed sharing of our own expertise but learning
from others.
Amongst the biological experts were clinicians de-
veloping novel treatments for brain cancers, biologists
developing in vitro models for various cancers, scient-
ists developing in vitro systems of testing different well
known stem-cell related candidate targets like Notch and
Hedgehog, those screening for epigenetic modifiers of the
stem cell phenotype and others like ourselves involved
in phenotypic screening.
Chemists also hailed from different branches, includ-
ing synthetic chemistry, producing steroids, retinoids
and other potential drugs, pharmaceutical chemistry, in
silico screening and development of chemical libraries.
These three groups worked within themselves, each
setting up different workshops at the different group
meetings. They also set up collaborative activities, such
as the development of a chemical database of different
kinds of agents for testing, from the chemists. However,
it later became clear that the best work and publications
would result from the development of cross-speciality
collaborations where biologists tested new chemicals in
their various test systems. In fact the three work-group
system whilst still a functional grouping, became less
significant as time went by. Numerous collaborations
have been developed over the period of the COST ac-
tion (although it is still ongoing) resulting in various
publications (Madeira et al., 2014; Christodoulou et al.,
2013; Majchrzak et al., 2013; Porcile et al., 2014).
Once the action was established, the first workshop
was held in Milan in July 2012 and two members from
our research group, Dr Pierre Schembri-Wismayer and
Dr Krystle Blaire Theuma attended. The meeting
was very well organised and showed many different ap-
proaches to tackling stem cells in Cancer, including both
the targeting of specific stem cell-related molecules us-
ing chemical approaches and the wider search of natural
or synthesised products for anti-stem cell activity using
a particular biological model system.
One of the main points about such meetings is that
apart from the consortium members themselves contrib-
uting, external speakers (usually experts in the field who
can contribute a new view point or angle to ongoing re-
search) are invited (and funded) to attend the different
meetings.
We presented some research work, using natural ex-
tracts for leukaemia differentiation. An oral presenta-
tion presented by PSW was entitled “Insect cell-extract
induces increased expression of differentiation markers
in HL60 leukaemia cells” whilst Dr Theuma (also a ma-
nagerial committee member in the STEMCHEM con-
sortium) presented a poster entitled “Combination of
DNA modifying agents and differentiation inducers can
enhance differentiation in HL60 leukaemia cells”, which
was work she had done in collaboration with Ms Ana-
lisse Cassar (Fig. 1).
The advantage of this was that since we were working
using phenotypic screening (looking for a biological ef-
fect which could lead to candidate compounds for drug
development and since we (mostly A. Cassar) has de-
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Figure 1: Dr Schembri-Wismayer and Dr Theuma presenting
their poster and discussing with Prof. Navakauskiene.
veloped this phenotypic screen into a relatively high
throughput system, many chemists in particular, were
interested in talking to us to assess their compounds.
The fact that the group’s area of expertise is also the less
commonly targeted mechanism of differentiation ther-
apy rather than cytotoxicity also increased interest.
Basically, we spectrophotometrically assess a leuko-
cyte differentiation-related enzymatic activity (NBTZ).
This is then divided by a mitochondrial activity which
acts as a surrogate for cell number giving us and indic-
ation of the average differentiation marker per cell (Fig.
2).
Figure 2: Schematic showing rationale behind screening tests.
At a second workshop meeting in Porto in February
2013, Analisse Cassar, another graduate student from
the same lab presented her paper “Effects of Insect
Conditioned Medium in Combination with Chromatin-
Modifying Agents on the Terminal Differentiation of
Leukaemia”. She was given a lot of good feedback
and I (PSW) received glowing reports of her very good
presentation of very interesting work from other very
authoritative STEMCHEM colleagues.
Analisse presented this work in the same session as a
colleague form Lithuania, Ruta Navakauskiene from Vil-
nius University, who presented complimentary and sim-
ilar work entitled “Effects of HDACI, HMTI and HMTI
in combination with retinoic acid on granulocytic differ-
entiation of human promyelocytic leukemia cells”. Our
lab and that of Prof. Navakauskiene have often found
that we are working on similar areas so sharing our ex-
pertise and skills in STEMCHEM has been useful in
turning us from primarily competitors to collaborators.
In fact, another post-graduate student in the lab, Mr
Sherif Suleiman, supervised by Dr Jean Calleja Agius,
the present head of the Anatomy department will hope-
fully be benefiting form a short term scientific mission
to Prof. Navakauskiene’s labs in Lithuania, where he
will be learning how to test for different chromatin-
modifying agents using molecular biology techniques not
presently in common use in our own labs. We on the
other hand have benefited from colleagues in Europe
visiting our lab, from Greece (officially funded as an
STSM) , Ireland and Serbia, through the STEMCHEM
consortium.
This is in fact the aim of a short terms scientific mis-
sion. This is funded as part of the action and involved
up to e300 for travel and e60–e90 as a daily allowance
up to a maximum of e2500 for a period up to 3 months
and in the case of early stage researchers (within 8 years
of a PhD), even up to e3500 for longer periods.
I should at this point make a little note as to the
various benefits of COST actions for our little nation.
Many countries have two management committee mem-
bers from two different labs. In our consortium, the
management committee members are always funded in
whatever conference or visit is organised, except when
specific meetings for young scientists for example are or-
ganized when there is no management committee meet-
ing . When possible, the Action also funds 1-2 parti-
cipants from each other member (i.e. each lab or uni-
versity involved in the action, since of course these may
involve numerous labs from the same country). Since
it is uncommon that too many researchers are involved
in a particular area, in Malta and since one is allowed
to have alternative management committee members,
should one be able to attend, then it allows good fund-
ing locally for research staff, and even students to have
the opportunity to present their work on a much wider
stage.
In fact following the different talks by the group, col-
laborations initially started as contacts from individual
labs who asked us to send certain chemicals for testing.
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One of the earliest of these was Dr Danijel Kikelj who
sent 12 chemicals for differentiation testing. Later Nad-
ine Martinet (initially an invited speaker from INSERM
in Nice in France and later a member of the consortium)
asked all chemistry labs to contribute towards a large
central chemical database which she administered and
this was made available to all the various biology labs.
As a result, we ended up screening over 600 chemicals
(and still have more to work on) from numerous labs
around Europe. Due to the large number of chemicals
needing work-up and due to the limited hands on deck in
terms of graduate students, more than 30 undergradu-
ate students participated in this research, also offering
undergraduate students (some of which are shown in
Fig. 4) an opportunity to understand the research com-
ponent of the University of Malta and contribute to in-
ternational science. More than 80 very interesting hits
(which cause leukaemia differentiation to different de-
grees) have been identified and many of these are being
followed up.
The first 400 or so chemicals screened were presen-
ted in a fourth meeting in Budapest in March 2014 (no
one from Malta attended the third meeting in Warsaw)
and again this garnered a lot of attention with various
labs interested in continuing collaborations. Some of the
chemicals presented are indicated in Fig. 3 where dif-
ferent novel synthesised chemicals (named only by their
catalogue number) are shown to be active in the screen-
ing method developed in our lab, again compared to
positive and negative controls. The more active of these
chemicals are then assessed by morphology – i.e. the
Figure 4: The students from the preclinical medical years who
performed the bulk of the work in testing the first 400 chemicals
on the STEMCHEM database.
effects of differentiation are assessed visually. Should
this also be interesting, further testing can be done by
means of flow cytometry (Fig. 5), locally to confirm the
expression of differentiated chemistry markers. In fact
this has resulted in students and post-docs from labs
in Ireland and Serbia visiting our labs and more should
be coming in the near future, from Greece and possibly
elsewhere.
Some of the chemicals from these labs have already
shown activity in 2 or more assays and will be followed
up for publication. The 80 or so hits from the first
four hundred screen and all the new hits from the last
200 chemicals will also be assessed with morphology and
flow cytometry and followed up accordingly with the
Figure 3: Some results out of the first 400 chemicals in the STEMCHEM chemical library, tested in the summer of 2013. Results
show an index of differentiation created by dividing a leukocyte differentiation marker (NBTZ reduction function) by an indicator of
cellular activity and thus of cell number (MTT activity). Results are an average of 3 replicates at each of two concentrations 1 and
10 mm. The first three columns show the results of negative control (normal culture medium) as well as two positive controls which
however cannot be used in the clinic due to toxicity, PMA and DMSO.
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Figure 5: Changes in the expression of CD14 marker (mono-
cytic differentiation) between untreated (violet) and treated (blue)
HL60 populations.
chemists who produced them.
The common way that this is done is that the chem-
ists make similar molecules to the hits and then these
are once again screened to see which variations are even
more active. The most active of these agents can then
be tested on numerous leukaemia cell lines (we usually
test 4 rather different myeloid leukaemias initially) and
then can even be tested on primary leukaemia blasts
from patients to see if the effect is also possible on pa-
tient cancers rather than the more artificial cell lines.
All this information enhances the possibility of develop-
ing effective drugs for inducing differentiation, a rather
novel kind of therapy for cancers, started a number of
years ago with all-trans retinoic acid, which converted
the normally fatal Acute promyelocytic leukaemia into
a manageable disease where more than 90% of patients
are cured nowadays.
Expanding this interesting branch of cancer therapy
is one of the main interests of our lab at the Anatomy
department and STEMCHEM has given us the capabil-
ity to open up our expertise to collaborations all across
Europe and to many more possible candidate drugs,
apart from our own in-house derived extracts.
Another development in our own lab is the indication
that many of these chemicals may also work on other
solid tumours apart from leukaemias, especially the ser-
ious solid tumours of childhood. There is already evid-
ence that all trans retinoic acid works to some extent on
brain and bone tumours (Choschzick et al., 2014; Yang
et al., 2012) but so do some of the extracts and drugs we
are testing. In fact our preliminary work on osteosarco-
mas (bone tumours) was presented by another graduate
student, Mr Sherif Suleiman (Fig. 6) at the last meet-
ing of the Action in October in Tenerife where a good
group of Action members enjoyed a meeting at one of
Europe’s more exotic destinations (Fig. 7).
Overall, COST actions offer extra funding for cash-
strapped local research groups to travel, and train, and
more importantly the opportunity to share data, dis-
cuss in a wider pan-European forum and set up col-
laborations which allow one to access larger sources of
funding such as Horizon 2020 or Innovative Medicines
Figure 6: Changes in Alkaline phosphatase expression divided
by indicator of total cell number assessing differentiation related
changes in osteosarcoma.
Figure 7: The poster of the last action workshop meeting in
Tenerife.
Initiative 2 funding. Importantly for our small country,
they also provide an opportunity for students to travel
and present their work. This was my first experience in
COST but it will definitely not be my last.
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